These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 27846751)
21. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. Matsuno H; Katayama K Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060 [TBL] [Abstract][Full Text] [Related]
22. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085 [TBL] [Abstract][Full Text] [Related]
23. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. Otsuka Y; Kiyohara C; Kashiwado Y; Sawabe T; Nagano S; Kimoto Y; Ayano M; Mitoma H; Akahoshi M; Arinobu Y; Niiro H; Akashi K; Horiuchi T PLoS One; 2018; 13(4):e0196368. PubMed ID: 29694426 [TBL] [Abstract][Full Text] [Related]
24. Histopathological changes of synovial tissue in rheumatoid arthritis patients treated with TNF-α inhibitors or IL-6 inhibitors. Takashima Y; Hayashi S; Maeda T; Fukuda K; Onoi Y; Tachibana S; Ikuta K; Anjiki K; Fujita M; Kikuchi K; Kamenaga T; Kuroda R; Matsubara T Clin Exp Rheumatol; 2022 Nov; 40(11):2060-2070. PubMed ID: 35084317 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115 [TBL] [Abstract][Full Text] [Related]
26. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538 [TBL] [Abstract][Full Text] [Related]
27. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289 [TBL] [Abstract][Full Text] [Related]
28. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318 [TBL] [Abstract][Full Text] [Related]
29. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P; Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890 [TBL] [Abstract][Full Text] [Related]
30. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045 [TBL] [Abstract][Full Text] [Related]
31. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. Woodrick RS; Ruderman EM Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733 [TBL] [Abstract][Full Text] [Related]
33. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA; Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961 [TBL] [Abstract][Full Text] [Related]
34. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. McLaughlin M; Östör A Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607 [TBL] [Abstract][Full Text] [Related]
35. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis. Kanbe K; Chen Q; Nakamura A; Hobo K Clin Rheumatol; 2011 Nov; 30(11):1407-13. PubMed ID: 21909699 [TBL] [Abstract][Full Text] [Related]
37. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Song SN; Yoshizaki K Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492 [TBL] [Abstract][Full Text] [Related]
38. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750 [TBL] [Abstract][Full Text] [Related]
39. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Ogata A; Kato Y; Higa S; Yoshizaki K Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250 [TBL] [Abstract][Full Text] [Related]
40. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]